Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants
January 24, 2023 08:00 ET
|
Nemaura Medical, Inc
Average weight loss of 3.7 pounds and an average BMI reduction of 0.6 after 10 weeks in initial patients LOUGHBOROUGH, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:...
Nemaura Medical to Present at the Sidoti & Co. Micro Cap Virtual Conference
January 11, 2023 08:00 ET
|
Nemaura Medical, Inc
Loughborough, England, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic...
SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients
January 09, 2023 08:25 ET
|
SeaStar Medical Holding Corporation
Building upon demonstrated clinical success, the pivotal study will evaluate the Selective Cytopheretic Device in adults with AKI requiring CKRT DENVER, Jan. 09, 2023 (GLOBE NEWSWIRE) --...
Nemaura Medical to Present at the Planet MIcroCap Showcase: Virtual 2022
December 01, 2022 08:15 ET
|
Nemaura Medical, Inc
Loughborough, England, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic...
SeaStar Medical Appoints Rick Barnett as Chairman of the Board of Directors
November 29, 2022 09:05 ET
|
SeaStar Medical Holding Corporation
DENVER, COLORADO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq:ICU), (“SeaStar Medical” or the “Company”), a medical technology company developing proprietary...
Nemaura Medical Reports Fiscal Second Quarter 2023 Results and Provides Business Update
November 15, 2022 08:00 ET
|
Nemaura Medical, Inc
Loughborough, England, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a...
Nemaura Medical to Present at the Bernstein 2ND Annual CGM Disruptors Conference
November 11, 2022 08:00 ET
|
Nemaura Medical, Inc
Loughborough, England, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic...
SeaStar Medical (Nasdaq: ICU) Announces Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children
November 03, 2022 09:00 ET
|
SeaStar Medical Holding Corporation
Data being presented at the American Society of Nephrology (ASN) Kidney Week 2022 Interim study data show that SCD treatment is safe to use in pediatric patients with Acute Kidney Injury (AKI)...
SeaStar Medical (NASDAQ: ICU) Commences Trading on Nasdaq Capital Market and Outlines Corporate Strategy and Near-Term Catalysts
October 31, 2022 09:25 ET
|
SeaStar Medical Holding Corporation
– Company advancing clinically proven platform therapy, the Selective Cytopheretic Device (SCD), to address the life-threatening consequences of hyperinflammation – SCD lead program in Acute...
Nemaura Receives Provisional Purchase Order from Middle East Licensee TPMENA
October 12, 2022 11:00 ET
|
Nemaura Medical, Inc
LOUGHBOROUGH, ENGLAND, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and...